$CURI/@CuriosityStream -- A platform "founded to satisfy humanity's enduring curiosity with premium content to inform, enchant & inspire.”

$CURI:
-benefits from the cord-cutting revolution
-claims a "factual streaming" niche

A @JoeySolitro pick & a post-merger SPAC

Thread 👇
The $CURI angle -- Subscription Video on Demand (SVoD) for solely non-fiction

$NFLX is to "movies & scripted drama"

as

@hulu is to "general entertainment"

as

$CURI is to "factual" -- delivering content covering:
-- science
-- history
-- tech
-- nature
-- lifestyle

& more
5 $CURI revenue streams (1/3)

a) Direct Subs
-- monthly & annual fees
-- accessible in 170 nations for anyone w/broadband
-- est. 25-35% of revs

b) Multichannel Video Programming Distribution (MVPD)
-- collects fixed fee
-- offered in pay TV packages
-- est. 25-35% of revs
5 $CURI revenue streams (2/3)

c) Program sales
-- compensated upon content delivery
-- pre-sells big originals to global media companies
-- est. 10-20% of revs

d) Ads
-- commercials on linear networks
-- sponsorships
-- multi-platform digital partnerships
-- est. 10-20% of revs
5 $CURI revenue streams (3/3)

e) Corporate Partnerships
-- multi-year agreements w/institutions for bulk subs
-- $CURI provides & operates a co-branded streaming service
-- 40 corporate clients to date
-- est. 10-20% of revs
Notes on Ad revenue:

a) $CURI launched ads last month
-- just starting to generate revenue from linear & multi-platform ads

b) Company's perceived ad TAM
-- 53M+ households globally
-- 5.6M+ USA subs

c) Integrates w/Apple, Roku, Xfinity etc.
Summary of flexible content delivery:

a) Acquires & produces content

b) Distribution via:
-- partner bundles w/ $CMCSA & more
-- Indirectly on platforms like $AMZN Prime
-- directly through @CuriosityStream
Management (1/3)

a. John Hendricks -- Founder & Chairman
-- founder of Discovery Communications 👀
-- American Film Institute Trustee
-- pumped $140M into starting $CURI

b. Clint Stinchcomb -- President & CEO
-- "founder/CEO for successful launch of networks/franchises/brands"
Management (2/3)

c. Jason Eustace -- CFO
-- former head of finance for Bluemercury, Pet360 & Discovery
Management (3/3)

Hendricks has purchased roughly $1.5M in shares this month... boosting his common equity stake by roughly 21.5%.

This may explain why 👇
Financials (1/3) -- $CURI's last Q:

a) Revs up 83% YOY to $8.7M
b) Gross margin (GM) up 200 bps YOY to 61%
c) -77.2% op margin vs. -210.9% YOY
e) 13M total paid subs (❗️total includes bundled subs❗️) up 108% YOY
-- on track to hit 2020 sub goals

FAR from free $. Getting there.
Financials (2/3) -- $CURI's 2020 forecasts:

a) Revs up 119% YOY to $39.5M
b) GM of 65% up 300 bps YOY
c) 32M total subs up 184% YOY
-- Aided by sub deal in India (covered later)
-- Direct subs up 68% to 895K
-- Corporate subs up 500% to 628K

50% CAGR through 2023 -- to get to👇
Financials (3/3) -- $CURI's 2023 forecasts:

a) $202M in revs
-- 79.9% growth in '21
-- 91% growth in '22
-- 49% growth in '23
b) 15% profit margin
-- roughly $30M in 2023 profit
c) 79M total subs
-- 2.1M direct subs via 27% 2022 growth
-- 2.6M corporate subs via 174% 2022 growth
Note on company Philosophy:

The management team views bundled distribution as vital to driving early subscription scale due to its newness in the market
-- comes w/less ARPU vs. direct to consumer
-- enables $CURI to reach the masses today
Market:

a) 🌎 Streaming -- Grand View
-- Sales $42.6B in 2019
-- 20.4% CAGR

b) 🌎 Streaming -- BusinessWire
-- Sales ~$45.6B in 2019
-- 18.3% CAGR

c) 🌎 SVoD -- Statista
-- Sales ~$46B in 2019
-- 10.7% CAGR
-- 11.9% user penetration in 2020 to 17.2% in 2025
The SPAC Deal:

50.9M pro-forma shares outstanding
-- excludes 23.3M shares in warrants & sponsor shares

= Fully diluted share count of ~74.2M
Absolute Valuation:

a) ~$760M market cap based on fully diluted count

b) ~$580M enterprise value when deducting $ balance (no debt)

So❗️IF❗️it hits its forecasts -- by 2023:

c) 19X EV/Profit

d) 2.8x EV/Sales
Relative Valuation:

a) $CURI
-- 8.1x 2021 EV/S
-- 79.9% growth
-- 64% GM

b) $NFLX
-- 8.1x 2021 EV/S
-- 40.3% growth
-- 40% GM

c) $ROKU
-- 9.5x 2021 EV/S
-- 32.7% growth
-- 44.5% GM

NOT 🍎 to 🍎 -- $CURI is MUCH smaller & further from free $ vs. others.

Still informative.
Notes from $CURI's Bernstein presentation (1/4)

**All Info from founder John Hendricks**

1) In November $CURI partnered w/Tata Sky (Indian streaming platform) w/~19M users
-- Tata is creating its own SVOD platform "Tata Sky Binge"
-- $CURI will be 1 of 25 services on it
Notes from $CURI's Bernstein presentation (2/4)

$CURI will grow from 3100 factual titles today to 12k in 2025
-- $NFLX has ~500
-- aims to be to factual entertainment as ESPN is to sports media (the main brand... not the only)
-- a laser-focus on factual will drive success
Notes from $CURI's Bernstein presentation (3/4)

$CURI average production cost vs. scripted alternative
-- $CURI: $500-600k for top end factual entertainment
-- scripted shows: $5-6M
-- GOThrones: $15M

Proceeds from public offering to cover production & promotion costs.
Notes from $CURI's Bernstein presentation (4/4)

Affordable content creation enables
-- scalable production despite having limited resources
-- subs for $2.99/month & $19.99/year

New subs are going w/annual option 4/5 times... creates industry-low churn according to Hendricks.
MGMT notes from last Q:

a) "Paid subs doubled while CAC dropped 18% & LTV grew 53%"
-- I want more commentary here

b) As a biz built to stream:
-- sells streaming ads w/out cannibalizing linear ad demand
-- networks need linear ad buyer demand; makes streaming shift challenging
Risks:

1) Streaming is crowded
-- rapid sub growth vital for $CURI
-- LOT of forecasting, need to execute

2) Sports halted in 2020
-- $CURI had no sports to compete with

3) Majority of subs via bundles
-- competition could decide they don't need $CURI
-- lower ARPU vs. direct
Plan:

This has started at 1% of my total holdings.

It will not exceed 2% cost basis.

If the company hits its long term forecasts, this should succeed.

I think it can do just that... BUT it's still a big if.

Long $CURI.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Brad Freeman

Brad Freeman Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @StockMarketNerd

6 Dec
Peeling back the layers of the $OZON -- a company striving to be Russian $AMZN.

Recent takeover interest from $SFTBY & $AMZN hints at its ability to do just that.

Unsurprisingly, a @JoeySolitro pick.

Time for a thread. 👇
$OZON's mission:

"Transforming the Russian consumer economy by offering the widest selection, best value & maximum online shopping convenience while empowering sellers to achieve greater commercial success."
The value proposition:

a. For active buyers
--Widest multi-category selection
--"Exceptional value & convenience"

b. For active sellers
--Access to larger audience
--Ozon fulfillment
--"Advanced analytics tools"
--Lending options 👀
--ad & data services
Read 26 tweets
4 Dec
A lot of interest in $LMND lately... I wonder why 📈👀🙂

Here are my complete thoughts... nothing has changed since this besides 2 earnings reports that made me more excited about the company if anything.

I'm long for the long term barring any abrupt changes to the thesis. 🍋
& some more details from CFO Tim Bixby at a recent investor conference.

Going over
-how $1 in premiums flows through $LMND's income statement
-how new reinsurance contracts help the businesses
-LTV/CAC

& more
Read 4 tweets
25 Nov
$LGVW to merge w/@ButterflyNetInc -- a disruptor in ultrasound.

Learned about it a few days ago & had a chance to dig in.

A thread 👇.
The product: "Butterfly IQ+"
-Puts ultrasound on a semiconductor
-Ushers in era of hand-held ultrasound
-Linear, curvilinear & phased array ultrasound probe all in 1
-Connects hardware w/integrated software, AI & tele-guidance to drive faster, smarter, less costly medical imaging
1. Notes from Dr. Jonathon Rothberg -- Founder & Chairman

The resume
-Pioneered a process to sequence genomes on a semiconductor
-Launched field of next-gen sequencing
-Won a Presidential Medal of Tech & innovation… casual
Read 25 tweets
30 Aug
Weekend theme: S-1s

peaked my interest.

THREAD TIME!
Problem w/healthcare:

"No guidance for what healthcare should cost with or without insurance" -Co-CEO Doug Hirsch

Leads to higher costs so that in USA:
-2/3 avoid care entirely
-20-30% of scripts are left at counter
-25% have no doc
Resulting unfortunate consequences:

For us: American dies every 4 mins from not taking prescribed medicine as directed

For Health system: 30% of ER visits could have been treated in other care settings. ER visits are expensive for all parties.

For pharmacies: Loss of sales
Read 20 tweets
19 Aug
Why I'm sipping on $LMND

THREAD TIME

@Lemonade_Inc A digitally-native insurance platform featuring

a) AI & machine learning to more accurately price risk & more affordably price plans
b) Philanthropy to make a shady industry friendlier
c) A quick, transparent buying process
The machine is learning:

In 2017: $LMND AI bots (Jim & Maya) handled 6% of inquiries.

Today 32%

There is every reason to believe the % will continue rising for this less than 4 y/o company.

Fosters lower customer acquisition cost that company passes on to users. (see below)
AI edge:

$LMND loss ratios improve w/scale; opposite of competition.

(Loss ratio=$ paid in claims/$ collected in premiums)

$LMND: .67

Industry ave: .82 (low is 👍)

Machines > human mind @ scaling

A young company used AI to be 15% better at pricing risk than 100 y/o firms.
Read 12 tweets
16 Aug
My investment philosophy (THREAD)

A) Identify stocks based on financial metrics such as:

rev growth/margin profile/op fcf & fcf trends/bs health/capital mgmt

Is growth powered solely by more opex, debt or equity dilution?

Is there any operating leverage apparent in business?
B) Study quality of products, competitive landscape, innovation pipeline, mgmt quality, & try to identify a strong moat.

Ask myself (& others) will products be growingly needed over 20 yrs? Is the company in a position to fill added demand?

Is it being disrupted or disrupting?
C) Listen to several past earnings calls & executive interviews to gage how timely & successful mgmt is w/executing stated goals.

Were predictions reliable or did they consistently miss the mark?

How smoothly are ops carried out?

Can I trust this mgmt team w/my $?
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!